微管蛋白Transgelin判断肝癌切除术预后的临床价值探讨

Transgelin expression in prognosis of hepatocellular carcinoma after hepatectomy

目的 研究肝癌中转胶蛋白（Transgelin）表达预测肝癌切除术患者复发及预后的临床意义.方法 应用组织芯片结合免疫组织化学染色检测43例肝癌切除术患者肝癌和癌周组织的Transgelin表达水平.以Logrank检验、Kaplan-Meier分析以及多因素Cox回归分析其表达水平与肝癌患者预后的关系.结果 Transgelin在肝癌组织中的表达明显高于癌旁组织,Transgelin在癌组织中的表达与肿瘤大小、门静脉癌栓、肿瘤TNM分期以及术前血清AFP水平呈正相关性.Transgelin阳性表达的患者术后无瘤生存率明显低于阴性表达者（P＜0.01）.多因素Cox回归分析显示,Transgelin是影响术后无瘤生存率的独立预后因素之一（P＜0.01）.结论 Transgelin与肝癌患者术后复发密切相关,可作为判断肝癌切除术预后的生物标志物.

Objective To study the clinical meaning of Transgelin expression in heptacellular carcinoma（HCC） in prognosing recurrence after hepatectomy. Methods The expression of Transgelin in cancerous lesions and tissue adjacent to cancer lesions from 223 operation samples was detected by immunohistochemical staining combined with tissue microarray techniques. The correlation between the level of Transgelin expression and the prognosis was analyzed by means of log- rank test, Kaplan- Meier analysis and multivariate Cox regression analysis. Results Transgelin was higher expressed in tumor tissue than in tissue adjacent to cancer lesions. Transgelin was positively correlated with the presence of tumor size, portal vein invasion, pTNM tumor stages and serum AFP level. Patients with positive expression of Transgelin had worse tumor free survival than those with negative ones （P 〈0. 01）. The multivariate Cox regression analysis showed that Transgelin expression level was one of the independent prognostic factors in tumor free survival after surgery. Conclusions The expression of Transgelin in hepatocellular carcinoma was significantly associated with recurrence in patients with HCC after hepatectomy, and this protein could be the biomarker of the prognosis in HCC surgery.